Spinal Muscular Atrophy Market
May 06, 2019
SMA (Spinal Muscular Atrophy) – a disease that takes away the physical strength of people by affecting the motor nerve cells in the spinal cord, also people have a problem in walking, eating, or breathing.
Spinal Muscular Atrophy market size is increasing at a CAGR of 10.42% for the study period (2017-2028). Need more information on SMA market.
Downloads
Click Here To Get the Article in PDF
Recent Articles
- Innovent Biologics reaps; Jeff Aronin’s lead; Alexion gives out; Stoke Therapeutics receives
- Biogen’s SPINRAZA Phase II/III Trial Results; Travere’s FILSPARI FDA Approval; GSK’s ...
- Top 12 Most Expensive Drugs in the US Healthcare Market
- Nucleic Acids and Gene Therapies in Neuromuscular Disorders: Next-Generation Therapeutic Strategies
- FDA Expands GSK’s Jemperli Approval; Biogen to Acquire Reata Pharma; Enhertu Shows Survival Boost...
Downloads
Article in PDF
Recent Articles
- Meet the World’s most expensive drug: Zolgensma
- Vedanta raises; Relay Therapeutics reels in; Gene therapy for SMA
- 7 Emerging Spinal Muscular Atrophy Therapies Offering Hope for Patients
- Biogen’s SPINRAZA Phase II/III Trial Results; Travere’s FILSPARI FDA Approval; GSK’s ...
- Spinal Muscular Atrophy Market is expected to augment at a CAGR of 10.42%
